

OCTOBER 20, 2005 - WASHINGTON DC

TITAN STENT VS TAXUS STENT

TCT 2005, results study

Dr Pasi Karjalainen from Satakunta Hospital Pori Hospital in Finland presented the data about the Titan stent Pori Registry during the Cardiovascular Research Foundation's 17th Annual Transcatheter Cardiovascular Therapeutics (TCT 2005) scientific symposia moderated by Dr E.Grube.

Dr Karjalainen included 195 consecutive patients treated for angioplasty with the Titan stent manufactured by Hexacath, and made a comparison with a second cohort of consecutive patients treated with the Taxus stent a product of Boston Scientific. The data demonstrated that the use of the Titan stent resulted in a lower overall Major Adverse Cardiac Event (MACE) at 30 days post procedure than with the Taxus stent (0% Vs.5.1%) with a lower rate of sub acute thrombosis for the Titan cohort (0% Vs 3.6%).

Patients were well matched in both cohorts: complex lesion (B/C) 88% for Titan stent Vs 78% for Taxus stent, Reference Vessel Diameter of 2.93mm for the Titan stent Vs. 3.04mm for the Taxus stent, lesion length of 12.9mm for the Titan stent Vs. 13.8 mm for the Taxus stent and percentage of diabetics of 17% for the Titan stent Vs 19% for the Taxus stent.

According to Dr Karjalainen, this study enrolled high risk patients with rates of Acute Myocardial Events of respectively 66% for the Titan stent Vs 44% for the Taxus stent.

The nine month clinical follow up also showed positive results in favor of the Titan stent Vs. the Taxus stent : MACE (death, heart attack, re-vascularization) were of 10.3% Vs 13.7%.

Dr Karjalainen concluded that the Titan stent is a safe and durable treatment option in the real world of unselected patients.